Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Commodity Chemicals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ENZY
- CUSIP: N/A
- Web: www.enzymotec.com
- Market Cap: $241.59 million
- Outstanding Shares: 22,949,000
- 50 Day Moving Avg: $8.62
- 200 Day Moving Avg: $8.56
- 52 Week Range: $5.20 - $10.94
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 49.09
- P/E Growth: 4.17
- Annual Revenue: $47.01 million
- Price / Sales: 5.27
- Book Value: $5.90 per share
- Price / Book: 1.83
- EBIDTA: ($4,560,000.00)
- Net Margins: -14.52%
- Return on Equity: -3.88%
- Return on Assets: -3.58%
- Current Ratio: 6.85%
- Quick Ratio: 4.72%
- Average Volume: 36,461 shs.
- Beta: 1.31
- Short Ratio: 1.26
Frequently Asked Questions for Enzymotec (NASDAQ:ENZY)
What is Enzymotec's stock symbol?
Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."
How were Enzymotec's earnings last quarter?
Enzymotec Ltd. (NASDAQ:ENZY) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.05 by $0.15. The firm had revenue of $13 million for the quarter, compared to analyst estimates of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The company's revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business earned $0.04 EPS. View Enzymotec's Earnings History.
When will Enzymotec make its next earnings announcement?
Where is Enzymotec's stock going? Where will Enzymotec's stock price be in 2017?
2 equities research analysts have issued 12-month target prices for Enzymotec's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Enzymotec's share price to reach $8.00 in the next year. View Analyst Ratings for Enzymotec.
What are analysts saying about Enzymotec stock?
Here are some recent quotes from research analysts about Enzymotec stock:
- 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (5/22/2017)
- 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)
Who are some of Enzymotec's key competitors?
Some companies that are related to Enzymotec include STAAR Surgical Company (STAA), Intra-Cellular Therapies (ITCI), Aceto Corporation (ACET), Antares Pharma (ATRS), Pacific Biosciences of California (PACB), Sucampo Pharmaceuticals (SCMP), WAVE Life Sciences (WVE), Capital Senior Living Corporation (CSU), Jounce Therapeutics (JNCE), G1 THERAPEUTICS (GTHX), AnaptysBio (ANAB), Surgery Partners (SGRY), Invacare Corporation (IVC), American Renal Associates Holdings (ARA), Entellus Medical (ENTL), AC Immune SA (ACIU), NantKwest (NK) and Assembly Biosciences (ASMB).
Who are Enzymotec's key executives?
Enzymotec's management team includes the folowing people:
- Steve Dubin, Independent Chairman of the Board
- Erez Israeli, President, Chief Executive Officer
- Yoav Doppelt, Independent Vice Chairman of the Board
- Oren Bryan, Chief Financial Officer, Vice President
- Yoav Kahane, Chairman of Advanced Lipids AB
- Yoni Twito, Chief Operating Officer
- Naama Zamir, Vice President - Human Resources and Information Systems
- Gai Ben-Dror, Vice President - Process Development
- Tzafra Cohen, Vice President - Research & Development
- Tamar D. Howson, Director
Who owns Enzymotec stock?
Enzymotec's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
BERESHEIT GENERAL PARTNER LTD.
(6.10%), Janus Henderson Group PLC (1.27%), Acadian Asset Management LLC (0.86%) and California Public Employees Retirement System (0.68%). View Institutional Ownership Trends for Enzymotec.
Who sold Enzymotec stock? Who is selling Enzymotec stock?
Enzymotec's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Laurion Capital Management LP, Menta Capital LLC, Public Employees Retirement System of Ohio and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Enzymotec.
Who bought Enzymotec stock? Who is buying Enzymotec stock?
How do I buy Enzymotec stock?
Shares of Enzymotec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzymotec's stock price today?
MarketBeat Community Rating for Enzymotec (NASDAQ ENZY)MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Enzymotec stock can currently be purchased for approximately $10.80.
Consensus Ratings for Enzymotec (NASDAQ:ENZY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$8.00 (25.93% downside)|
Analysts' Ratings History for Enzymotec (NASDAQ:ENZY)
(Data available from 8/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|2/23/2017||Jefferies Group LLC||Reiterated Rating||Hold||$8.00||N/A|
|11/17/2016||Wells Fargo & Company||Downgrade||Outperform -> Market Perform||N/A|
|4/17/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
Earnings History for Enzymotec (NASDAQ:ENZY)Earnings History by Quarter for Enzymotec (NASDAQ ENZY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/16/2017||6/30/2017||$0.05||($0.10)||$12.78 million||$13.00 million||View||N/A|
|5/17/2017||3/31/2017||$0.06||$0.03||$14.23 million||$12.00 million||View||N/A|
|2/22/2017||Q416||$0.03||($0.10)||$11.47 million||$10.60 million||View||N/A|
|11/16/2016||Q316||$0.07||$0.03||$13.29 million||$11.40 million||View||N/A|
|8/9/2016||Q216||$0.08||$0.04||$14.90 million||$15.00 million||View||N/A|
|5/19/2016||Q116||$0.05||$0.09||$13.85 million||$14.00 million||View||Listen|
|2/17/2016||Q415||$0.10||$0.07||$14.01 million||$13.30 million||View||Listen|
|11/11/2015||Q315||$0.07||$0.08||$14.21 million||$12.40 million||View||Listen|
|8/12/2015||Q215||$0.06||$0.11||$12.39 million||$13.40 million||View||Listen|
|5/7/2015||Q115||$0.06||$0.09||$12.10 million||$12.25 million||View||N/A|
|2/18/2015||Q414||$0.08||$0.06||$11.11 million||$10.80 million||View||N/A|
|11/13/2014||Q314||$0.04||$0.05||$10.22 million||$9.50 million||View||N/A|
|8/5/2014||Q214||$0.10||$0.02||$14.88 million||$11.50 million||View||N/A|
|5/14/2014||Q114||$0.17||$0.24||$19.40 million||$23.70 million||View||N/A|
|2/13/2014||Q413||$0.11||$0.15||$11.64 million||$18.51 million||View||N/A|
|11/11/2013||Q313||$0.11||$0.13||$13.10 million||$22.50 million||View||Listen|
Earnings Estimates for Enzymotec (NASDAQ:ENZY)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Enzymotec (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Enzymotec (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Enzymotec (NASDAQ:ENZY)
Latest Headlines for Enzymotec (NASDAQ:ENZY)
|Jefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)|
www.americanbankingnews.com - August 21 at 3:38 AM
|BRIEF-Enzymotec Ltd Q2 loss per share $0.10|
www.reuters.com - August 17 at 7:38 PM
|Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results|
finance.yahoo.com - August 16 at 4:01 PM
|Enzymotec reports 2Q loss|
finance.yahoo.com - August 16 at 4:01 PM
|Enzymotec Ltd. (ENZY) Announces Quarterly Earnings Results, Misses Estimates By $0.15 EPS|
www.americanbankingnews.com - August 16 at 10:38 AM
|Enzymotec Ltd. (NASDAQ:ENZY) Upgraded to Hold by ValuEngine|
www.americanbankingnews.com - August 12 at 8:20 PM
|Enzymotec Ltd. (NASDAQ:ENZY) Scheduled to Post Quarterly Earnings on Wednesday|
www.americanbankingnews.com - August 9 at 7:18 AM
|Quaker Chemical Corporation (KWR) & Enzymotec (ENZY) Head to Head Contrast|
www.americanbankingnews.com - August 8 at 10:18 PM
|BRIEF-Frutarom reports 9.63 pct stake in Enzymotec ltd as of August 1|
www.reuters.com - August 5 at 10:32 PM
|BRIEF-Frutarom reports 7.57 pct stake in Enzymotec|
www.reuters.com - July 31 at 11:05 PM
|Enzymotec (ENZY) Announces Appointment of Dror Israel as CFO|
www.streetinsider.com - July 29 at 10:30 PM
|BRIEF-Enzymotec Ltd appoints Dror Israel as CFO|
www.reuters.com - July 29 at 10:30 PM
|Enzymotec to Report Second Quarter 2017 Financial Results|
finance.yahoo.com - July 26 at 6:55 PM
|BRIEF-Beresheit General Partner reports 6.1 pct passive stake in Enzymotec|
www.reuters.com - July 18 at 5:20 AM
|BRIEF-Enzymotec CFO to step down|
www.reuters.com - June 29 at 4:01 AM
|Form 6-K Enzymotec Ltd. For: Jun 28|
www.streetinsider.com - June 29 at 4:01 AM
|Enzymotec Chief Financial Officer to Step Down|
finance.yahoo.com - June 28 at 6:00 PM
|Jefferies Group Comments on Enzymotec Ltd.'s Q3 2017 Earnings (ENZY)|
www.americanbankingnews.com - June 23 at 8:50 AM
|Jefferies Group Weighs in on Enzymotec Ltd.'s Q2 2017 Earnings (ENZY)|
www.americanbankingnews.com - June 22 at 7:38 AM
|Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017|
finance.yahoo.com - June 14 at 6:09 PM
|Weakness Seen in Enzymotec (ENZY) Estimates: Should You Stay Away?|
finance.yahoo.com - June 13 at 12:01 PM
|Enzymotec Ltd (ENZY) Sees Significant Drop in Short Interest|
www.americanbankingnews.com - June 11 at 7:32 AM
|Enzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold|
finance.yahoo.com - June 6 at 5:24 PM
|Enzymotec Ltd. to Present at the Jefferies 2017 Global Healthcare Conference|
finance.yahoo.com - May 25 at 6:59 PM
|Enzymotec Ltd (ENZY) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - May 22 at 7:34 PM
|Enzymotec Ltd (ENZY) Releases Earnings Results, Misses Expectations By $0.03 EPS|
www.americanbankingnews.com - May 20 at 12:32 AM
|Enzymotec Ltd (ENZY) Issues Quarterly Earnings Results|
www.americanbankingnews.com - May 19 at 9:46 PM
|Enzymotec Ltd (ENZY) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS|
www.americanbankingnews.com - May 19 at 2:26 PM
|Enzymotec Ltd (ENZY) Posts Earnings Results, Misses Expectations By $0.03 EPS|
www.americanbankingnews.com - May 18 at 8:12 AM
|Investor Network: Enzymotec Ltd. to Host Earnings Call|
finance.yahoo.com - May 17 at 10:56 AM
|Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results|
finance.yahoo.com - May 17 at 10:56 AM
|Enzymotec misses 1Q profit forecasts|
finance.yahoo.com - May 17 at 10:56 AM
|Zacks: Enzymotec Ltd (ENZY) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - May 12 at 2:38 PM
|Enzymotec (ENZY) Getting Positive Media Coverage, Report Finds|
www.americanbankingnews.com - May 3 at 3:50 PM
|Enzymotec to Report First Quarter 2017 Financial Results|
finance.yahoo.com - May 3 at 8:53 AM
|VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods|
finance.yahoo.com - May 2 at 7:27 PM
|Enzymotec Ltd (ENZY) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - April 28 at 10:36 PM
|Enzymotec (ENZY) Getting Somewhat Negative Press Coverage, Study Shows|
www.americanbankingnews.com - April 21 at 12:49 PM
|Enzymotec (ENZY) Getting Somewhat Positive Press Coverage, Analysis Finds|
www.americanbankingnews.com - April 17 at 9:03 PM
| Enzymotec Ltd (ENZY) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - April 13 at 6:28 PM
|ENZYMOTEC LTD. Financials|
finance.yahoo.com - March 22 at 5:11 PM
| Enzymotec Ltd (ENZY) Given Consensus Recommendation of "" by Brokerages|
www.americanbankingnews.com - March 21 at 10:49 AM
|Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016|
finance.yahoo.com - March 16 at 6:22 PM
|Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders|
feeds.benzinga.com - March 10 at 9:04 AM
|Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO|
finance.yahoo.com - March 9 at 5:32 PM
|8:33 am Enzymotec appoints Erez Israeli as President and CEO effective April 18|
finance.yahoo.com - March 9 at 5:32 PM
|BRIEF-Enzymotec Q4 non-GAAP loss per share $0.10|
www.reuters.com - February 22 at 7:55 AM
|Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results|
finance.yahoo.com - February 22 at 7:55 AM
|ENZY : Summary for Enzymotec Ltd. - Yahoo Finance|
finance.yahoo.com - February 13 at 10:51 PM
|Enzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results|
finance.yahoo.com - February 6 at 9:43 AM
Enzymotec (ENZY) Chart for Tuesday, August, 22, 2017